Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

X4 Pharmaceuticals (XFOR) Cost of Revenue (2024 - 2025)

X4 Pharmaceuticals' Cost of Revenue history spans 2 years, with the latest figure at $364000.0 for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 20.53% year-over-year to $364000.0; the TTM value through Dec 2025 reached $5.8 million, up 622.33%, while the annual FY2025 figure was $5.8 million, 622.33% up from the prior year.
  • Cost of Revenue reached $364000.0 in Q4 2025 per XFOR's latest filing, up from $351000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $4.7 million in Q1 2025 to a low of $227000.0 in Q3 2024.